Fig. 5: Commercial vaccine stem-epitope availability and cross-reactive immunogenicity. | Nature Communications

Fig. 5: Commercial vaccine stem-epitope availability and cross-reactive immunogenicity.

From: Commercial influenza vaccines vary in HA-complex structure and in induction of cross-reactive HA antibodies

Fig. 5

a ELISA binding analysis of commercial vaccines (Fluad (blue), Flublok (purple), Fluzone HD (red), Flucelvax (green)) by HA stem monoclonal antibodies (FI6v3, CR6261, C179). Vaccine samples were normalized for H1 HA amount prior to plating. Recombinant H1 HA protein (H1 HA A/Michigan/45/21015, black dots) was a positive control with saline (white dots) as the negative control (F (10, 36) = 7.219, p < 0.0001). b Schedule for immunization of mice with vaccines with day 35 sera used in subsequent ELISA studies. c–f The endpoint titer levels of different vaccine sera were compared for cross-reactivity to different recombinant proteins: c H1 head (N = 15 mice, F (3, 56) = 32.86, p < 0.0001), d H1 stem (N = 15 mice, F (3, 56) = 10.77, p < 0.0001), e H2 HA (N = 5 mice, F (3, 16) = 20.16 p < 0.0001), and f H7 HA (N = 5 mice, F (3, 16) = 38.08, p < 0.0001). PBS control sera were also tested to determine threshold, but not shown. Graphs display the mean with standard error of the mean bars and asterisks to denote statistical differences (p < 0.05, Tukey’s multiple comparisons test with two-tailed significance).

Back to article page